Top 3 Stocks Poised to Outperform the Market by 2026
Investors are always on the lookout for stocks that are likely to outperform the market. As we move towards 2026, several companies appear poised for significant growth. Below are three stocks that have strong fundamentals and upcoming catalysts that could drive their performance in the stock market.
Top 3 Stocks Poised to Outperform the Market by 2026
1. Alphabet Inc. (GOOG)
Alphabet, the parent company of Google, has shown impressive growth over the past year. Despite a recent downturn, its future looks promising, particularly due to its advancements in artificial intelligence and cloud services. The company’s CFO, Anat Ashkenazi, reported that Google Cloud’s backlog increased by 55% from the previous quarter and more than doubled year-over-year, reaching $240 billion.
As Google Cloud converts this backlog into recognized revenue throughout 2026, earnings are expected to rise significantly. The growth is driven partly by customers adopting Google Cloud’s enterprise AI products, which utilize the robust Gemini 3.0 AI models.
- Current Price: $305.65
- Market Cap: $3.7 trillion
- 52-week Range: $140.53 – $349.00
- Dividend Yield: 0.27%
2. BeOne Medicines (ONC)
BeOne Medicines, formerly known as BeiGene, stands out as a promising biotech stock. The company has already made waves with its leading blood cancer treatment, Brukinsa. Recent market share gains indicate a bright future for this product, which is positioned to compete effectively against existing therapies.
Multiple catalysts are on the horizon for BeOne: a Phase 3 study of Brukinsa combined with rituximab is expected to produce results in the first half of 2026. Additionally, the company plans to seek U.S. regulatory approval for sonrotoclax, targeting relapsed mantle cell lymphoma, and may file for accelerated approval for another drug by year-end.
- Current Price: $346.07
- Market Cap: $38 billion
- 52-week Range: $196.45 – $385.22
3. Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals is another mid-cap biotech company to watch. Currently, the firm markets Imcivree, a drug approved for rare genetic obesity disorders. A pivotal decision by the FDA regarding Imcivree’s approval for treating acquired hypothalamic obesity is anticipated by March 20, 2026. If approval is granted, market momentum is likely to surge.
Rhythm also expects to release critical clinical data in 2026, including results from studies focusing on additional genetic diseases and Prader-Willi syndrome, affecting approximately 400,000 people globally. This represents a significant potential market for the company.
- Current Price: $98.03
- Market Cap: $6.5 billion
- 52-week Range: $45.91 – $122.20
In conclusion, these three stocks—Alphabet, BeOne Medicines, and Rhythm Pharmaceuticals—are strategically positioned with vital catalysts expected to impact their performance positively by 2026. As always, investors should conduct thorough research before making investment decisions and remain aware of market conditions.
